Ertumaxomab
From Wikipedia, the free encyclopedia
|
Ertumaxomab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Chimeric mouse/rat |
| Target | HER2/neu CD3 |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ertumaxomab (marketed under the brand name Rexomun) is a rat-murine hybrid monoclonal antibody which is used to treat some cancers.
|
|||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
